For oral solid-dose peptide APIs destined to tablet and capsule compression, coupling reagent selection is evaluated by the purgeability of post-reaction byproducts. N,N′-disuccinimidyl carbonate reacts with a protected amino acid to generate a succinimidyl active ester, carbon dioxide, and N-hydroxysuccinimide. The active ester is then coupled with an amino acid ester or amine in the same reactor sequence. Because carbon dioxide and N-hydroxysuccinimide are removed by phase separation and aqueous bicarbonate washing, this route is selected where carbodiimide-derived dicyclohexylurea would otherwise contaminate the crystal cake. On a 100 L glass-lined stirred reactor equipped with a retreat-curve impeller, the DSC activation step is run in anhydrous acetonitrile or tetrahydrofuran at a jacket set point of 0–5 °C. The carbonate is charged under nitrogen, and the CO₂ evolution is vented through a pressure-rated condenser to avoid foaming. A tertiary amine catalyst is metered into the reaction mass over 60–120 min, with the vessel pressure maintained below the reactor vent rating. The resulting peptide crude is isolated by drowning into cold purified water, filtered, and washed with 5% w/w sodium bicarbonate solution. The washed cake is analyzed by HPLC for N-hydroxysuccinimide content before final drying. For oral tablet and capsule applications, residual solvent in the dried API is controlled under ICH Q3C(R8); acetonitrile, when used, is reduced below 410 ppm and tetrahydrofuran below 720 ppm before release. Residual N-hydroxysuccinimide is specified as an unspecified impurity under ICH Q3A(R2), with the acceptance criterion set by the daily dose of the drug product. During downstream formulation, the peptide API is blended with microcrystalline cellulose, lactose monohydrate, and crospovidone for direct compression, or with mannitol and sodium starch glycolate for dry granulation. The final tablet or capsule is tested for content uniformity per USP <905> and dissolution per USP <711>. The route is suited to short-chain peptide APIs where the succinimidyl ester intermediate remains soluble in the reaction solvent and where the finished dosage form is not sensitive to trace succinimide-related impurities.

When Is DSC Selected Over Carbodiimide Coupling in Injectable Peptide API Synthesis?

DSC is selected for injectable peptide API manufacturing when the therapeutic peptide is shorter than approximately 15 amino acids and solution-phase coupling is more economical than solid-phase synthesis. The avoidance of dicyclohexylurea is decisive; dicyclohexylurea is sparingly soluble in common workup solvents and can persist into the final peptide if not removed by column chromatography. DSC instead releases N-hydroxysuccinimide, which is extracted into the aqueous phase at pH 7–8, and carbon dioxide, which is volatile. For injectable-grade material, the crude peptide is purified by preparative reversed-phase HPLC using C18 columns with particle sizes of 5 µm or 10 µm. The mobile phase consists of acetonitrile and water with 0.1% v/v trifluoroacetic acid; after fraction pooling, the peptide is converted to the acetate salt by ion exchange. The pooled peptide solution is passed through a 0.22 µm filter before lyophilization in a GMP freeze dryer. The lyophilization cycle includes primary drying at −25 °C to −15 °C shelf temperature and secondary drying at 20–25 °C chamber pressure of 50–100 Pa. The API is released against Ph. Eur. 2.6.14 and USP <85> with an endotoxin limit calculated from the maximum bolus dose. The table below summarizes residual solvent limits applied in this route.

During roller-compacted granulation of oral peptide APIs prepared by DSC-mediated solution-phase coupling, the dried API particle size and residual impurity profile determine whether the batch can be processed into granules without segregation. The coupling step is run to completion at the succinimidyl ester stage; incomplete activation leaves residual protected amino acid that is later rejected by HPLC purification. For granule line operation, the purified peptide is pre-milled through a conical mill fitted with a 0.5 mm screen, then blended with mannitol, microcrystalline cellulose, and crospovidone in a bin blender for 20–30 min at 6–10 rpm. The blend is compacted on a roller compactor with smooth rolls; ribbon density is monitored to keep granule friability below the limit required for capsule filling. After milling through 0.8 mm and 1.0 mm screens, the granules are dried in a fluid bed until loss on drying by USP <731> is below 1.0% w/w. The granulated final blend is filled into hard gelatin capsules or compressed into tablets. In this downstream operation, the upstream DSC step remains relevant because residual N-hydroxysuccinimide can form hygroscopic regions on the peptide surface at elevated relative humidity. Published data for the specific interaction between residual succinimide and granule compactability is limited; therefore, a conservative internal limit for N-hydroxysuccinimide is applied at API release to reduce batch-to-batch variation. The finished capsules are tested for dissolution per USP <711> Apparatus 2 at 50 rpm in 900 mL of buffered medium at 37 °C. Content uniformity is assessed by USP <905>.

Residual Succinimide Control in Long-Acting Depot Peptide Synthesis

Long-acting injectable depot formulations based on poly(lactide-co-glycolide) or polylactic acid microspheres require peptide API with low levels of coupling-derived nucleophilic byproducts because the encapsulated peptide resides in a degrading polymer matrix for 30 days to 180 days after intramuscular or subcutaneous injection. The DSC-mediated coupling route introduces N-hydroxysuccinimide as the main nonvolatile byproduct; although free N-hydroxysuccinimide is water-soluble and largely removed during aqueous workup, residual levels can be carried into the final peptide if lyophilization is performed from a solution that was not sufficiently diafiltered. For depot applications, the peptide solution is subjected to tangential flow filtration with a 1 kDa to 5 kDa regenerated cellulose membrane before lyophilization. The diafiltration endpoint is confirmed by HPLC-UV at 210 nm until the N-hydroxysuccinimide peak is below the method quantitation limit. The microsphere manufacturing process uses a water-in-oil-in-water double emulsion. The peptide aqueous phase is prepared by dissolving the API in purified water with a bulking agent such as trehalose; the organic phase consists of PLGA dissolved in dichloromethane. The primary emulsion is formed by high-shear mixing at 10,000–25,000 rpm depending on target particle size, and the secondary emulsion is formed under paddle stirring. Solvent evaporation is conducted under reduced pressure, and the hardened microspheres are washed with water for injection. Residual dichloromethane in the final microsphere product is controlled under USP <467>; the limit for dichloromethane is 600 ppm per ICH Q3C(R8). Sterility and bacterial endotoxins are tested on the final vialed product per USP <71> and USP <85>. The DSC-specific impurity control is integrated into the API release specification because the downstream microsphere process does not include a chromatographic purification step capable of removing small polar impurities after encapsulation.

If the Final Dosage Form Requires Terminal Sterilization by Filtration, Particulate Byproduct Management Becomes Critical

In injectable peptide drug product manufacturing where the final solution is terminally sterilized by filtration rather than autoclaving, the upstream DSC-based coupling route is audited for its effect on filterability. N-hydroxysuccinimide is highly water-soluble; under normal workup conditions it partitions into the aqueous mother liquor and is removed before the peptide is precipitated. If washing is incomplete, residual N-hydroxysuccinimide can co-precipitate with the peptide and later dissolve in the formulation buffer, but it does not typically form visible precipitates. The more critical filterability risk is particulate matter generated from insufficiently controlled crystallization of the peptide after coupling; this is unrelated to the reagent but must be controlled to achieve subvisible particle counts below the USP <788> limits. During drug product compounding, the peptide solution is passed through a polyethersulfone or PVDF membrane with a nominal pore size of 0.22 µm. The filtration train is installed with a pressure gauge upstream and downstream, and the differential pressure is monitored to avoid membrane plugging. If the peptide concentration exceeds 10 mg/mL, the solution is often prefiltered through a 0.45 µm membrane before the terminal 0.22 µm filter. Filter integrity is tested by bubble point or diffusive flow per the membrane manufacturer’s validation. For aseptic processing, the final product is filled into glass vials under Grade A laminar airflow and tested for sterility per USP <71> and Ph. Eur. 2.6.1. The acceptance criterion for subvisible particles in small-volume injections is not more than 6,000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm under USP <788> Method 1. DSC itself is not present in the final formulation; the audit focuses on removal of its byproducts because filterability is sensitive to residual small-molecule impurities that alter viscosity or surface tension.

Because oral peptide formulations in capsule formats increasingly use enteric-coated multi-particulate systems, the upstream coupling chemistry must deliver an API with a particle size distribution narrow enough for suspension layering onto inert cores. DSC-mediated solution-phase coupling followed by preparative HPLC and lyophilization typically yields an amorphous or microcrystalline powder. The dried powder is jet-milled or conical-milled to a d90 below 200 µm before it is dispersed in an aqueous binder solution containing hypromellose and triethyl citrate. The dispersion is sprayed onto sugar spheres in a fluid-bed coater fitted with a Wurster insert; inlet air temperature is maintained between 35 °C and 45 °C and the spray rate is adjusted to keep the product temperature below 30 °C. After drug layering, the beads are coated with an enteric methacrylic acid copolymer dispersion such as Eudragit L 30 D-55, followed by curing at 40 °C for 2 h. Dissolution of the finished enteric-coated capsules is tested per USP <711> using a two-stage medium: 0.1 N HCl for 2 h, followed by pH 6.8 phosphate buffer. The DSC-step residues are controlled at the API stage because the fluid-bed layering process does not include a purification step. If residual N-hydroxysuccinimide remains above the internal threshold, the resulting bead surfaces may show increased tack during the curing phase, although published data for this specific configuration is limited; therefore, a conservative release limit is applied before the API is released for layering.